| Year |
Citation |
Score |
| 2024 |
Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, ... ... Mulligan MJ, et al. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials. Npj Vaccines. 9: 67. PMID 38553525 DOI: 10.1038/s41541-024-00833-z |
0.433 |
|
| 2024 |
Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, Lai L, Tsong R, Kao CM, Raabe V, El Sahly HM, Keitel WA, Whitaker JA, Smith MJ, Schmader KE, ... ... Mulligan MJ, et al. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 38537255 DOI: 10.1093/cid/ciae173 |
0.393 |
|
| 2023 |
Ivanova EN, Shwetar J, Devlin JC, Buus TB, Gray-Gaillard S, Koide A, Cornelius A, Samanovic MI, Herrera A, Mimitou EP, Zhang C, Karmacharya T, Desvignes L, Ødum N, Smibert P, ... ... Mulligan MJ, et al. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. Iscience. 26: 108572. PMID 38213787 DOI: 10.1016/j.isci.2023.108572 |
0.396 |
|
| 2023 |
Kottkamp AC, Samanovic MI, Duerr R, Oom AL, Belli HM, Zucker JR, Rosen JB, Mulligan MJ. Antibody Titers against Mpox Virus after Vaccination. The New England Journal of Medicine. 389: 2299-2301. PMID 38091537 DOI: 10.1056/NEJMc2306239 |
0.412 |
|
| 2023 |
Smith TC, Espinoza DO, Zhu Y, Cardona-Ospina JA, Bowman NM, Becker-Dreps S, Rouphael N, Rodriguez-Morales AJ, Bucardo F, Edupuganti S, Premkumar L, Mulligan MJ, de Silva AM, Collins MH. Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes. Ebiomedicine. 98: 104875. PMID 37983984 DOI: 10.1016/j.ebiom.2023.104875 |
0.397 |
|
| 2023 |
Duerr R, Dimartino D, Marier C, Zappile P, Wang G, François F, Ortigoza MB, Iturrate E, Samanovic MI, Mulligan MJ, Heguy A. Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study. Ebiomedicine. 97: 104843. PMID 37866115 DOI: 10.1016/j.ebiom.2023.104843 |
0.325 |
|
| 2023 |
Ibaraki M, Lai L, Huerta C, Natrajan MS, Collins MH, Anderson EJ, Mulligan MJ, Rouphael N, Moe CL, Liu P. Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum. Research Square. PMID 37790500 DOI: 10.21203/rs.3.rs-3153900/v1 |
0.335 |
|
| 2023 |
Zhang B, Upadhyay R, Hao Y, Samanovic MI, Herati RS, Blair JD, Axelrad J, Mulligan MJ, Littman DR, Satija R. Multimodal single-cell datasets characterize antigen-specific CD8 T cells across SARS-CoV-2 vaccination and infection. Nature Immunology. 24: 1725-1734. PMID 37735591 DOI: 10.1038/s41590-023-01608-9 |
0.385 |
|
| 2023 |
Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, ... ... Mulligan MJ, et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nature Medicine. PMID 37640860 DOI: 10.1038/s41591-023-02503-4 |
0.376 |
|
| 2023 |
Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. PMID 37451878 DOI: 10.1016/j.vaccine.2023.06.032 |
0.371 |
|
| 2023 |
Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, et al. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. Npj Vaccines. 8: 98. PMID 37433788 DOI: 10.1038/s41541-023-00693-z |
0.377 |
|
| 2023 |
Parameswaran L, Jaysing A, Ding H, Wilkenfeld M, Dean R, Wilson KK, Frank O, Duerr R, Mulligan MJ. Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities. Journal of Racial and Ethnic Health Disparities. PMID 37391605 DOI: 10.1007/s40615-023-01680-9 |
0.363 |
|
| 2023 |
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, ... ... Mulligan M, et al. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Research Square. PMID 37205592 DOI: 10.21203/rs.3.rs-2653179/v1 |
0.399 |
|
| 2023 |
Zhang B, Upadhyay R, Hao Y, Samanovic MI, Herati RS, Blair J, Axelrad J, Mulligan MJ, Littman DR, Satija R. Multimodal characterization of antigen-specific CD8 T cells across SARS-CoV-2 vaccination and infection. Biorxiv : the Preprint Server For Biology. PMID 36747786 DOI: 10.1101/2023.01.24.525203 |
0.351 |
|
| 2023 |
Raabe V, Lai L, Morales J, Xu Y, Rouphael N, Davey RT, Mulligan MJ. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP). Vaccine. 41: 1513-1523. PMID 36725433 DOI: 10.1016/j.vaccine.2023.01.059 |
0.439 |
|
| 2022 |
Samanovic MI, Oom AL, Cornelius AR, Gray-Gaillard SL, Karmacharya T, Tuen M, Wilson JP, Tasissa MF, Goins S, Herati RS, Mulligan MJ. Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines. Vaccines. 10. PMID 36560562 DOI: 10.3390/vaccines10122152 |
0.413 |
|
| 2022 |
Gray-Gaillard SL, Solis S, Monteiro C, Chen HM, Ciabattoni G, Samanovic MI, Cornelius AR, Williams T, Geesey E, Rodriguez M, Ortigoza MB, Ivanova EN, Koralov SB, Mulligan MJ, Herati RS. Molecularly distinct memory CD4+ T cells are induced by SARS-CoV-2 infection and mRNA vaccination. Biorxiv : the Preprint Server For Biology. PMID 36415470 DOI: 10.1101/2022.11.15.516351 |
0.349 |
|
| 2022 |
Lai L, Rouphael N, Xu Y, Kabbani S, Beck A, Sherman A, Anderson EJ, Bellamy A, Weiss J, Cross K, Mulligan MJ. An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT) cells and antibody responses. Vaccine. PMID 36273986 DOI: 10.1016/j.vaccine.2022.09.041 |
0.383 |
|
| 2022 |
Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S, Valeria Calderon A, Dibba F, Stanzin I, Samanovic MI, Raut P, ... ... Mulligan MJ, et al. Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies. Annals of Clinical and Translational Neurology. PMID 36165097 DOI: 10.1002/acn3.51664 |
0.368 |
|
| 2022 |
Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, ... ... Mulligan MJ, et al. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. Medrxiv : the Preprint Server For Health Sciences. PMID 35898343 DOI: 10.1101/2022.07.12.22277336 |
0.366 |
|
| 2022 |
Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, ... Mulligan MJ, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Reports. Medicine. 100679. PMID 35798000 DOI: 10.1016/j.xcrm.2022.100679 |
0.376 |
|
| 2022 |
Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Kelly C, Olsen-Chen C, Novak RM, Brady RC, Pasetti M, DeFranco E, Gerber JS, Shriver M, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). Medrxiv : the Preprint Server For Health Sciences. PMID 35734087 DOI: 10.1101/2022.06.13.22276354 |
0.32 |
|
| 2022 |
Blank RB, Haberman RH, Qian K, Samanovic M, Castillo R, Jimenez Hernandez A, Vasudevapillai Girija P, Catron S, Uddin Z, Rackoff P, Solomon G, Azar N, Rosenthal P, Izmirly P, Samuels J, ... ... Mulligan MJ, et al. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis. Rheumatology (Oxford, England). PMID 35640110 DOI: 10.1093/rheumatology/keac322 |
0.328 |
|
| 2022 |
Tada T, Zhou H, Dcosta BM, Samanovic MI, Chivukula V, Herati RS, Hubbard SR, Mulligan MJ, Landau NR. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. Ebiomedicine. 78: 103944. PMID 35465948 DOI: 10.1016/j.ebiom.2022.103944 |
0.391 |
|
| 2022 |
Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Herati RS, Mulligan MJ, Landau NR. Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. Frontiers in Immunology. 13: 797589. PMID 35350781 DOI: 10.3389/fimmu.2022.797589 |
0.36 |
|
| 2022 |
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. The New England Journal of Medicine. PMID 35081293 DOI: 10.1056/NEJMoa2116414 |
0.385 |
|
| 2022 |
Tada T, Zhou H, Dcosta BM, Samanovic MI, Cornelius A, Herati RS, Mulligan MJ, Landau NR. High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals. Cell Reports. 38: 110237. PMID 34982967 DOI: 10.1016/j.celrep.2021.110237 |
0.357 |
|
| 2021 |
Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. Iscience. 24: 103341. PMID 34723159 DOI: 10.1016/j.isci.2021.103341 |
0.329 |
|
| 2021 |
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, et al. Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report. Medrxiv : the Preprint Server For Health Sciences. PMID 34671773 DOI: 10.1101/2021.10.10.21264827 |
0.389 |
|
| 2021 |
Izmirly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, Engel AJ, Masson M, Xie X, Cornelius AR, Herati RS, Haberman RH, Scher JU, Guttmann A, Blank RB, ... ... Mulligan MJ, et al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. Arthritis & Rheumatology (Hoboken, N.J.). PMID 34347939 DOI: 10.1002/art.41937 |
0.311 |
|
| 2021 |
Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ, Landau NR. Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. Biorxiv : the Preprint Server For Biology. PMID 34312623 DOI: 10.1101/2021.07.19.452771 |
0.363 |
|
| 2021 |
Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR, Tada T. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. Mbio. e0138621. PMID 34311587 DOI: 10.1128/mBio.01386-21 |
0.336 |
|
| 2021 |
Rouphael NG, Lai L, Tandon S, McCullough MP, Kong Y, Kabbani S, Natrajan MS, Xu Y, Zhu Y, Wang D, O'Shea J, Sherman A, Yu T, Henry S, McAllister D, ... ... Mulligan MJ, et al. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. Npj Vaccines. 6: 89. PMID 34262052 DOI: 10.1038/s41541-021-00353-0 |
0.452 |
|
| 2021 |
Tada T, Dcosta BM, Samanovic MI, Herati RS, Cornelius A, Zhou H, Vaill A, Kazmierski W, Mulligan MJ, Landau NR. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. Mbio. e0069621. PMID 34060334 DOI: 10.1128/mBio.00696-21 |
0.318 |
|
| 2021 |
Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov S, Atreya R, Tascilar K, Allen J, Castillo R, Cornelius A, Rackoff P, Solomon G, Adhikari S, ... ... Mulligan M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases. PMID 34035003 DOI: 10.1136/annrheumdis-2021-220597 |
0.304 |
|
| 2021 |
Carmody ER, Zander D, Klein EJ, Mulligan MJ, Caplan AL. Knowledge and Attitudes Toward Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community. Journal of Community Health. 46: 1161-1169. PMID 33999317 DOI: 10.1007/s10900-021-00995-0 |
0.334 |
|
| 2021 |
Ivanova EN, Devlin JC, Buus TB, Koide A, Cornelius A, Samanovic MI, Herrera A, Zhang C, Desvignes L, Odum N, Ulrich R, Mulligan MJ, Koide S, Ruggles KV, Herati RS, et al. Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus infection. Medrxiv : the Preprint Server For Health Sciences. PMID 33907755 DOI: 10.1101/2021.04.20.21255677 |
0.373 |
|
| 2021 |
Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR, Tada T. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. Biorxiv : the Preprint Server For Biology. PMID 33791698 DOI: 10.1101/2021.03.24.436620 |
0.334 |
|
| 2021 |
Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz G, Ali M, Koralov SB, Mulligan MJ, Herati RS. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. Medrxiv : the Preprint Server For Health Sciences. PMID 33594383 DOI: 10.1101/2021.02.07.21251311 |
0.404 |
|
| 2021 |
Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, Landau NR. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. Biorxiv : the Preprint Server For Biology. PMID 33564768 DOI: 10.1101/2021.02.05.430003 |
0.353 |
|
| 2021 |
Salerno-Gonçalves R, Chen WH, Mulligan MJ, Frey SE, Stapleton JT, Keitel WA, Bailey J, Sendra E, Hill H, Johnson RA, Sztein MB. Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation. Clinical & Translational Immunology. 10: e1239. PMID 33505681 DOI: 10.1002/cti2.1239 |
0.401 |
|
| 2021 |
Winokur P, El Sahly HM, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. Vaccine. PMID 33485646 DOI: 10.1016/j.vaccine.2020.11.051 |
0.34 |
|
| 2020 |
Sherman AC, Lai L, Bower M, Natrajan MS, Huerta C, Karmali V, Kleinhenz J, Xu Y, Rouphael N, Mulligan MJ. The Effects of Imprinting and Repeated Seasonal Influenza Vaccination on Adaptive Immunity after Influenza Vaccination. Vaccines. 8. PMID 33171854 DOI: 10.3390/vaccines8040663 |
0.417 |
|
| 2020 |
Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England Journal of Medicine. PMID 33053279 DOI: 10.1056/NEJMoa2027906 |
0.368 |
|
| 2020 |
Kraft CS, Mehta AK, Varkey JB, Lyon GM, Vanairsdale S, Bell S, Burd EM, Sexton ME, Cassidy LA, Olinger P, Rengarajan K, Raabe VN, Davis E, Henderson S, DesRoches P, ... ... Mulligan MJ, et al. Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States. Infection Control and Hospital Epidemiology. 41: 385-390. PMID 32933606 DOI: 10.1017/Ice.2019.349 |
0.333 |
|
| 2020 |
Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, et al. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. Medrxiv : the Preprint Server For Health Sciences. PMID 32839784 DOI: 10.1101/2020.08.17.20176651 |
0.354 |
|
| 2020 |
Frew PM, Paine MB, Rouphael N, Schamel J, Chung Y, Mulligan MJ, Prausnitz MR. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity. Vaccine. PMID 32792250 DOI: 10.1016/J.Vaccine.2020.07.064 |
0.484 |
|
| 2020 |
Mulligan MJ. An Inactivated Virus Candidate Vaccine to Prevent COVID-19. Jama. 324: 943-945. PMID 32789500 DOI: 10.1001/Jama.2020.15539 |
0.515 |
|
| 2020 |
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. PMID 32785213 DOI: 10.1038/s41586-020-2639-4 |
0.329 |
|
| 2020 |
Maner-Smith KM, Goll JB, Khadka M, Jensen TL, Colucci JK, Gelber CE, Albert CJ, Bosinger SE, Franke JD, Natrajan M, Rouphael N, Johnson RA, Sanz P, Anderson EJ, Hoft DF, ... Mulligan MJ, et al. Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination. Vaccines. 8. PMID 32722213 DOI: 10.3390/Vaccines8030414 |
0.356 |
|
| 2020 |
Chang YH, Duong DM, Goll JB, Wood DC, Jensen TL, Yin L, Gelber CE, Seyfried NT, Anderson E, Natrajan MS, Rouphael N, Johnson RA, Sanz P, Mulligan MJ, Hoft DF. Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine. Vaccines. 8. PMID 32722207 DOI: 10.3390/Vaccines8030413 |
0.308 |
|
| 2020 |
Goll JB, Li S, Edwards JL, Bosinger SE, Jensen TL, Wang Y, Hooper WF, Gelber CE, Sanders KL, Anderson EJ, Rouphael N, Natrajan MS, Johnson RA, Sanz P, Hoft D, ... Mulligan MJ, et al. Transcriptomic and Metabolic Responses to a Live-Attenuated Vaccine. Vaccines. 8. PMID 32722194 DOI: 10.3390/Vaccines8030412 |
0.307 |
|
| 2020 |
Ellebedy AH, Nachbagauer R, Jackson KJL, Dai YN, Han J, Alsoussi WB, Davis CW, Stadlbauer D, Rouphael N, Chromikova V, McCausland M, Chang CY, Cortese M, Bower M, Chennareddy C, ... ... Mulligan MJ, et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America. PMID 32661157 DOI: 10.1073/Pnas.1906613117 |
0.488 |
|
| 2020 |
Lai L, Ault K, Rouphael N, Beck A, Domjahn B, Xu Y, Anderson EJ, Cheng A, Nakamura A, Hoagland RJ, Kelley C, Edupuganti S, Mask K, Nesin M, Unger ER, ... ... Mulligan MJ, et al. Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. Vaccines. 8. PMID 32629943 DOI: 10.3390/Vaccines8030348 |
0.446 |
|
| 2020 |
Stapleford KA, Mulligan MJ. A New Vaccine for Chikungunya Virus. Jama. 323: 1351-1352. PMID 32286634 DOI: 10.1001/Jama.2020.2070 |
0.501 |
|
| 2020 |
Lai L, Rouphael N, Xu Y, Sherman AC, Edupuganti S, Anderson EJ, Lankford-Turner P, Wang D, Keitel W, McNeal MM, Cross K, Hill H, Bellamy AR, Mulligan MJ. Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine. Vaccines. 8. PMID 32183105 DOI: 10.3390/vaccines8010126 |
0.427 |
|
| 2020 |
Anderson EJ, Lai L, Wrammert J, Kabbani S, Xu Y, Priyamvada L, Hill H, Goll JB, Jensen TL, Kao C, Yildirim I, Rouphael N, Jackson L, Mulligan MJ. Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine. Vaccines. 8. PMID 32041104 DOI: 10.3390/vaccines8010069 |
0.331 |
|
| 2019 |
Natrajan MS, Rouphael N, Lai L, Kazmin D, Jensen TL, Weiss DS, Ibegbu C, Sztein MB, Hooper WF, Hill H, Anderson EJ, Johnson R, Sanz P, Pulendran B, Goll JB, ... Mulligan MJ, et al. Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses. Vaccines. 8. PMID 31878161 DOI: 10.3390/Vaccines8010004 |
0.42 |
|
| 2019 |
Rasheed MAU, Hickman CJ, McGrew M, Sowers SB, Mercader S, Hopkins A, Grimes V, Yu T, Wrammert J, Mulligan MJ, Bellini WJ, Rota PA, Orenstein WA, Ahmed R, Edupuganti S. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proceedings of the National Academy of Sciences of the United States of America. PMID 31481612 DOI: 10.1073/Pnas.1905570116 |
0.475 |
|
| 2019 |
Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, et al. Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial. Journal of Virology. PMID 31434737 DOI: 10.1128/Jvi.02041-18 |
0.532 |
|
| 2018 |
Sullivan NL, Reuter-Monslow MA, Sei J, Durr E, Davis CW, Chang C, McCausland M, Wieland A, Krah D, Rouphael N, Mehta AK, Mulligan MJ, Pulendran B, Ahmed R, Vora KA. . Journal of Virology. PMID 29743372 DOI: 10.1128/Jvi.00269-18 |
0.47 |
|
| 2018 |
Whatney WE, Gandhi NR, Lindestam Arlehamn CS, Nizam A, Wu H, Quezada MJ, Campbell A, Allana S, Kabongo MM, Khayumbi J, Muchiri B, Ongalo J, Tonui J, Sasser LE, Fergus TJ, ... ... Mulligan MJ, et al. A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in HumanInfection. Journal of Immunology (Baltimore, Md. : 1950). PMID 29540577 DOI: 10.4049/Jimmunol.1701737 |
0.333 |
|
| 2018 |
Widdice LE, Hoagland R, Callahan ST, Kahn JA, Harrison CJ, Pahud BA, Frey SE, Berry AA, Kotloff KL, Edwards KM, Mulligan MJ, Sudman J, Nakamura A, Bernstein DI. Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series. Vaccine. PMID 29428177 DOI: 10.1016/J.Vaccine.2017.12.060 |
0.41 |
|
| 2018 |
Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A. Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. The Journal of Infectious Diseases. PMID 29409017 DOI: 10.1093/Infdis/Jix653 |
0.416 |
|
| 2018 |
Anderson AM, Tyor WR, Mulligan MJ, Waldrop-Valverde D, Lennox JL, Letendre SL. HIV p24 antigen is quantifiable at low concentrations in human cerebrospinal fluid with digital ELISA and is associated with decreased neuropsychological performance. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29385540 DOI: 10.1093/Cid/Ciy056 |
0.339 |
|
| 2018 |
Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, ... ... Mulligan M, et al. Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505. The Journal of Infectious Diseases. PMID 29325070 DOI: 10.1093/Infdis/Jiy008 |
0.56 |
|
| 2018 |
Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, Pahud BA, Edwards KM, Mulligan MJ, Sudman J, Bernstein DI. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. PMID 29306506 DOI: 10.1016/J.Vaccine.2017.12.042 |
0.364 |
|
| 2018 |
Sahly HME, Gorchakov R, Murray K, Patel S, Atmar RL, Keitel W, Hoft D, Barrett J, Bailey J, Rouphael N, Edupuganti S, Raabe V, Wu H, Fairley J, Natrajan M, ... ... Mulligan MJ, et al. 2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients Open Forum Infectious Diseases. 5: S748-S748. DOI: 10.1093/Ofid/Ofy210.2144 |
0.329 |
|
| 2017 |
Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. PMID 29279281 DOI: 10.1016/J.Vaccine.2017.12.061 |
0.463 |
|
| 2017 |
Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA, Abdelsamed HA, McGuire DJ, Cohen KW, Alexe G, Nagar S, McCausland MM, Gupta S, Tata P, ... ... Mulligan MJ, et al. Origin and differentiation of human memory CD8 T cells after vaccination. Nature. PMID 29236685 DOI: 10.1038/Nature24633 |
0.379 |
|
| 2017 |
Painter JE, Temple BS, Woods LA, Cwiak C, Haddad LB, Mulligan MJ, DiClemente RJ. Theory-Based Analysis of Interest in an HIV Vaccine for Reasons Indicative of Risk Compensation Among African American Women. Health Education & Behavior : the Official Publication of the Society For Public Health Education. 1090198117736860. PMID 29073834 DOI: 10.1177/1090198117736860 |
0.525 |
|
| 2017 |
Lai L, Rouphael N, Xu Y, Natrajan MS, Beck A, Hart M, Feldhammer M, Feldpausch A, Hill C, Wu H, Fairley JK, Lankford-Turner P, Kasher N, Rago P, Hu YJ, ... ... Mulligan MJ, et al. Innate, T and B Cell Responses in Acute Human Zika Patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29020226 DOI: 10.1093/Cid/Cix732 |
0.334 |
|
| 2017 |
Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, et al. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. PMID 28750854 DOI: 10.1016/J.Vaccine.2017.07.024 |
0.461 |
|
| 2017 |
Waggoner JJ, Rouphael N, Xu Y, Natrajan M, Lai L, Patel SM, Levit RD, Edupuganti S, Mulligan MJ. Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler. Open Forum Infectious Diseases. 4: ofx103. PMID 28702470 DOI: 10.1093/Ofid/Ofx103 |
0.327 |
|
| 2017 |
Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, Pewin W, Frew PM, Yu T, Thornburg NJ, Kabbani S, Lai L, Vassilieva EV, Skountzou I, Compans RW, ... Mulligan MJ, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet (London, England). PMID 28666680 DOI: 10.1016/S0140-6736(17)30575-5 |
0.346 |
|
| 2017 |
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, Levin MJ. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. Journal of Immunology (Baltimore, Md. : 1950). PMID 28607114 DOI: 10.4049/Jimmunol.1700290 |
0.381 |
|
| 2017 |
Painter JE, DiClemente RJ, Jimenez L, Stuart T, Sales JM, Mulligan MJ. Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial. Vaccine. PMID 28533053 DOI: 10.1016/J.Vaccine.2017.05.024 |
0.488 |
|
| 2017 |
Li S, Sullivan NL, Rouphael N, Yu T, Banton S, Maddur MS, McCausland M, Chiu C, Canniff J, Dubey S, Liu K, Tran V, Hagan T, Duraisingham S, Wieland A, ... ... Mulligan MJ, et al. Metabolic Phenotypes of Response to Vaccination in Humans. Cell. PMID 28502771 DOI: 10.1016/J.Cell.2017.04.026 |
0.483 |
|
| 2017 |
Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. PMID 28256358 DOI: 10.1016/J.Vaccine.2017.02.032 |
0.483 |
|
| 2017 |
Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, ... Mulligan MJ, et al. Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial. The Journal of Infectious Diseases. PMID 28199679 DOI: 10.1093/Infdis/Jix086 |
0.567 |
|
| 2017 |
Murray KO, Gorchakov R, Carlson AR, Berry R, Lai L, Natrajan M, Garcia MN, Correa A, Patel SM, Aagaard K, Mulligan MJ. Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood. Emerging Infectious Diseases. 23. PMID 27748649 DOI: 10.3201/Eid2301.161394 |
0.341 |
|
| 2016 |
Kelley CF, Kraft CS, de Man TJ, Duphare C, Lee HW, Yang J, Easley KA, Tharp GK, Mulligan MJ, Sullivan PS, Bosinger SE, Amara RR. The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention. Mucosal Immunology. PMID 27848950 DOI: 10.1038/Mi.2016.97 |
0.439 |
|
| 2016 |
Spearman P, Mulligan M, Anderson EJ, Shane AL, Stephens K, Gibson T, Hartwell B, Hannaman D, Watson NL, Singh K. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation. Vaccine. PMID 27697302 DOI: 10.1016/J.Vaccine.2016.09.041 |
0.448 |
|
| 2016 |
Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith AR, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Reports. PMID 27481466 DOI: 10.1016/J.Celrep.2016.07.049 |
0.404 |
|
| 2016 |
Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, Ahmed R, Suthar MS, Wrammert J. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America. PMID 27354515 DOI: 10.1073/Pnas.1607931113 |
0.377 |
|
| 2016 |
Robinson HL, Mulligan MJ. Editorial overview: Preventive and therapeutic vaccines. Current Opinion in Virology. 17: viii-x. PMID 27283522 DOI: 10.1016/j.coviro.2016.05.006 |
0.368 |
|
| 2016 |
Kelley CF, Lai L, Ibegbu C, Rosenberg ES, Kaur S, Patel K, Mulligan MJ, Marconi VC, Sullivan PS, Amara RR. Differences in expression of gut-homing receptors on CD4+T cells in black and white HIV-negative men who have sex with men. Aids (London, England). PMID 26891038 DOI: 10.1097/Qad.0000000000001062 |
0.366 |
|
| 2015 |
Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, Frasca D, Gersten M, Mehta AK, Gaujoux R, Li GM, Gupta S, Ahmed R, Mulligan MJ, Shen-Orr S, et al. Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures. Immunity. 43: 1186-98. PMID 26682988 DOI: 10.1016/J.Immuni.2015.11.012 |
0.494 |
|
| 2015 |
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, et al. Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083). The Journal of Infectious Diseases. PMID 26475930 DOI: 10.1093/Infdis/Jiv496 |
0.553 |
|
| 2015 |
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, ... ... Mulligan M, et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infectious Diseases. 2: ofv082. PMID 26199949 DOI: 10.1093/Ofid/Ofv082 |
0.575 |
|
| 2015 |
Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, Sahly HE, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Chaplin P, Belshe RB, ... ... Mulligan M, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine. PMID 26143613 DOI: 10.1016/J.Vaccine.2015.06.075 |
0.36 |
|
| 2015 |
Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, Diclemente RJ, Wingood GM, Frew PM, Salazar LF, Del Rio C, Mulligan MJ, Peterson JL. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. Annals of Epidemiology. 25: 445-54. PMID 25911980 DOI: 10.1016/J.Annepidem.2015.03.006 |
0.347 |
|
| 2015 |
Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ, Rubinson L, Ströher U, Wolcott M, Dorman W, ... ... Mulligan MJ, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. Jama. 313: 1249-55. PMID 25742465 DOI: 10.1001/Jama.2015.1995 |
0.499 |
|
| 2015 |
Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, Miller JD, Pulendran B, Antia R, Ahmed R. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proceedings of the National Academy of Sciences of the United States of America. 112: 3050-5. PMID 25713354 DOI: 10.1073/Pnas.1500475112 |
0.434 |
|
| 2015 |
Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old. The Journal of Infectious Diseases. 212: 552-61. PMID 25649171 DOI: 10.1093/Infdis/Jiv056 |
0.465 |
|
| 2015 |
Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, et al. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 33: 163-73. PMID 25444805 DOI: 10.1016/J.Vaccine.2014.10.083 |
0.471 |
|
| 2014 |
Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, et al. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infectious Diseases. 1: ofu102. PMID 25734170 DOI: 10.1093/Ofid/Ofu102 |
0.503 |
|
| 2014 |
Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Jama. 312: 1420-8. PMID 25291578 DOI: 10.1001/Jama.2014.12609 |
0.485 |
|
| 2014 |
Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Jama. 312: 1409-19. PMID 25291577 DOI: 10.1001/Jama.2014.12854 |
0.433 |
|
| 2014 |
Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, García-Sastre A, ... Mulligan MJ, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America. 111: 13133-8. PMID 25157133 DOI: 10.1073/Pnas.1414070111 |
0.451 |
|
| 2014 |
Peterson JL, Bakeman R, Sullivan P, Millett GA, Rosenberg E, Salazar L, DiClemente RJ, Cooper H, Kelley CF, Mulligan MJ, Frew P, del Rio C. Social discrimination and resiliency are not associated with differences in prevalent HIV infection in black and white men who have sex with men. Journal of Acquired Immune Deficiency Syndromes (1999). 66: 538-43. PMID 24820109 DOI: 10.1097/Qai.0000000000000203 |
0.319 |
|
| 2014 |
Chiu C, McCausland M, Sidney J, Duh FM, Rouphael N, Mehta A, Mulligan M, Carrington M, Wieland A, Sullivan NL, Weinberg A, Levin MJ, Pulendran B, Peters B, Sette A, et al. Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. Plos Pathogens. 10: e1004008. PMID 24675761 DOI: 10.1371/Journal.Ppat.1004008 |
0.462 |
|
| 2014 |
Sullivan PS, Peterson J, Rosenberg ES, Kelley CF, Cooper H, Vaughan A, Salazar LF, Frew P, Wingood G, Diclemente R, del Rio C, Mulligan M, Sanchez TH. Understanding racial HIV/STI disparities in black and white men who have sex with men: a multilevel approach. Plos One. 9: e90514. PMID 24608176 DOI: 10.1371/Journal.Pone.0090514 |
0.306 |
|
| 2014 |
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. The Journal of Infectious Diseases. 210: 99-110. PMID 24403557 DOI: 10.1093/Infdis/Jiu003 |
0.528 |
|
| 2014 |
Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK, ... Mulligan MJ, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nature Immunology. 15: 195-204. PMID 24336226 DOI: 10.1038/Ni.2789 |
0.503 |
|
| 2014 |
Mulligan MJ, Bernstein D, Winokur P, Rupp R, Lai L, Anderson EJ, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman PW, Kabbani S, Ince D, Noah DL, Hill H, et al. LB-2Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response Open Forum Infectious Diseases. 1: S66-S67. DOI: 10.1093/Ofid/Ofu083.02 |
0.446 |
|
| 2013 |
Painter J, Cene-Kush C, Conner A, Cwiak C, Haddad L, Mulligan M, DiClemente R. Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women. Vaccines. 1: 88-104. PMID 26343960 DOI: 10.3390/Vaccines1020088 |
0.528 |
|
| 2013 |
Frew PM, Shapiro ET, Lu L, Edupuganti S, Keyserling HL, Mulligan MJ. Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine. Tropical Medicine & Surgery. 1: 117. PMID 25221781 DOI: 10.4172/2329-9088.1000117 |
0.436 |
|
| 2013 |
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. The New England Journal of Medicine. 369: 2083-92. PMID 24099601 DOI: 10.1056/Nejmoa1310566 |
0.524 |
|
| 2013 |
Edupuganti S, Eidex RB, Keyserling H, Akondy RS, Lanciotti R, Orenstein W, del Rio C, Pan Y, Querec T, Lipman H, Barrett A, Ahmed R, Teuwen D, Cetron M, Mulligan MJ, et al. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. The American Journal of Tropical Medicine and Hygiene. 88: 172-7. PMID 23208880 DOI: 10.4269/Ajtmh.2012.12-0179 |
0.536 |
|
| 2012 |
Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. The Lancet. Infectious Diseases. 12: 966-76. PMID 23174382 DOI: 10.1016/S1473-3099(12)70243-8 |
0.552 |
|
| 2012 |
Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. The American Journal of Tropical Medicine and Hygiene. 87: 1112-5. PMID 23109371 DOI: 10.4269/Ajtmh.2012.12-0182 |
0.457 |
|
| 2012 |
Eckard AR, Judd SE, Ziegler TR, Camacho-Gonzalez AF, Fitzpatrick AM, Hadley GR, Grossmann RE, Seaton L, Seydafkan S, Mulligan MJ, Rimann N, Tangpricha V, McComsey GA. Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antiviral Therapy. 17: 1069-78. PMID 22894927 DOI: 10.3851/Imp2318 |
0.354 |
|
| 2012 |
Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. The Journal of Infectious Diseases. 206: 811-20. PMID 22782949 DOI: 10.1093/Infdis/Jis427 |
0.488 |
|
| 2012 |
Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 9047-52. PMID 22615367 DOI: 10.1073/Pnas.1118979109 |
0.493 |
|
| 2012 |
Fuchs JD, Frank I, Kochar N, Elizaga M, Allen M, Carter D, Frahm N, Kalams SA, Mulligan M, Sheets R, Pensiero M, Clarke D, Eldridge J. First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine Retrovirology. 9: 134. DOI: 10.1186/1742-4690-9-S2-P134 |
0.499 |
|
| 2011 |
Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, Spearman P, Hill H, Wolff M. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. The Journal of Infectious Diseases. 203: 666-73. PMID 21282194 DOI: 10.1093/Infdis/Jiq093 |
0.446 |
|
| 2011 |
Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, ... ... Mulligan MJ, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of Experimental Medicine. 208: 181-93. PMID 21220454 DOI: 10.1084/Jem.20101352 |
0.417 |
|
| 2010 |
Frew PM, Mulligan MJ, Hou SI, Chan K, del Rio C. Time will tell: community acceptability of HIV vaccine research before and after the "Step Study" vaccine discontinuation. Open Access Journal of Clinical Trials. 2010: 149-156. PMID 21152413 DOI: 10.2147/Oajct.S11915 |
0.531 |
|
| 2010 |
Frew PM, Archibald M, Diallo DD, Hou SI, Horton T, Chan K, Mulligan MJ, del Rio C. An extended model of reasoned action to understand the influence of individual- and network-level factors on African Americans' participation in HIV vaccine research. Prevention Science : the Official Journal of the Society For Prevention Research. 11: 207-18. PMID 20012200 DOI: 10.1007/S11121-009-0162-9 |
0.445 |
|
| 2009 |
Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, Keyserling HL, Ploss A, Rice CM, Orenstein WA, Mulligan MJ, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. Journal of Immunology (Baltimore, Md. : 1950). 183: 7919-30. PMID 19933869 DOI: 10.4049/Jimmunol.0803903 |
0.375 |
|
| 2009 |
Mulligan M. Mark Mulligan leads Emory swine flu vaccine trial. Interview by Brooke Grindlinger. The Journal of Clinical Investigation. 119: 2438. PMID 19739283 DOI: 10.1172/jci40661 |
0.362 |
|
| 2009 |
Mulligan MJ. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Current Infectious Disease Reports. 11: 399-406. PMID 19698284 DOI: 10.1007/S11908-009-0056-9 |
0.531 |
|
| 2009 |
Poland GA, Mulligan MJ. The imperative of influenza vaccines for elderly individuals-an evolving story. The Journal of Infectious Diseases. 200: 161-3. PMID 19508160 DOI: 10.1086/599791 |
0.404 |
|
| 2009 |
Frew PM, del Rio C, Lu L, Clifton S, Mulligan MJ. Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial. Journal of Acquired Immune Deficiency Syndromes (1999). 50: 314-9. PMID 19194310 DOI: 10.1097/Qai.0B013E3181945Eec |
0.475 |
|
| 2009 |
Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. Aids Research and Human Retroviruses. 25: 103-14. PMID 19108693 DOI: 10.1089/Aid.2008.0212 |
0.42 |
|
| 2009 |
Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, ... ... Mulligan M, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunology. 10: 116-25. PMID 19029902 DOI: 10.1038/Ni.1688 |
0.475 |
|
| 2008 |
Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. Jama. 300: 1532-43. PMID 18827210 DOI: 10.1001/Jama.300.13.1532 |
0.334 |
|
| 2008 |
Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 28: 710-22. PMID 18468462 DOI: 10.1016/J.Immuni.2008.02.020 |
0.358 |
|
| 2008 |
Frew PM, del Rio C, Clifton S, Archibald M, Hormes JT, Mulligan MJ. Factors influencing HIV vaccine community engagement in the urban South. Journal of Community Health. 33: 259-69. PMID 18389351 DOI: 10.1007/S10900-008-9086-8 |
0.447 |
|
| 2007 |
Frew PM, Archibald M, Martinez N, del Rio C, Mulligan MJ. Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement? Challenge (Atlanta, Ga.). 13: 61-97. PMID 20686675 |
0.326 |
|
| 2007 |
Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. Aids Research and Human Retroviruses. 23: 67-76. PMID 17263635 DOI: 10.1089/Aid.2006.0114 |
0.458 |
|
| 2007 |
Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. Journal of Acquired Immune Deficiency Syndromes (1999). 44: 203-12. PMID 17106277 DOI: 10.1097/01.Qai.0000248356.48501.Ff |
0.537 |
|
| 2006 |
Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults Aids Research and Human Retroviruses. 22: 678-683. PMID 16831092 DOI: 10.1089/Aid.2006.22.678 |
0.524 |
|
| 2004 |
Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, Sabbaj S, Mulligan MJ, Goepfert PA. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. Aids Research and Human Retroviruses. 20: 972-88. PMID 15585085 DOI: 10.1089/Aid.2004.20.972 |
0.395 |
|
| 2004 |
Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. The Journal of Infectious Diseases. 190: 903-7. PMID 15295694 DOI: 10.1086/423284 |
0.524 |
|
| 2003 |
Bansal A, Sabbaj S, Edwards BH, Ritter D, Perkins C, Tang J, Szinger JJ, Weiss H, Goepfert PA, Korber B, Wilson CM, Kaslow RA, Mulligan MJ. T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. Aids Research and Human Retroviruses. 19: 1017-26. PMID 14678609 DOI: 10.1089/088922203322588378 |
0.403 |
|
| 2003 |
Sabbaj S, Bansal A, Ritter GD, Perkins C, Edwards BH, Gough E, Tang J, Szinger JJ, Korber B, Wilson CM, Kaslow RA, Mulligan MJ, Goepfert PA. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. Journal of Acquired Immune Deficiency Syndromes (1999). 33: 426-38. PMID 12869831 DOI: 10.1097/00126334-200308010-00003 |
0.44 |
|
| 2002 |
Sabbaj S, Edwards BH, Ghosh MK, Semrau K, Cheelo S, Thea DM, Kuhn L, Ritter GD, Mulligan MJ, Goepfert PA, Aldrovandi GM. Human immunodeficiency virus-specific CD8(+) T cells in human breast milk. Journal of Virology. 76: 7365-73. PMID 12097549 DOI: 10.1128/Jvi.76.15.7365-7373.2002 |
0.444 |
|
| 2002 |
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, ... Mulligan M, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndromes (1999). 29: 254-61. PMID 11873074 |
0.444 |
|
| 2002 |
Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. Journal of Virology. 76: 2298-305. PMID 11836408 DOI: 10.1128/Jvi.76.5.2298-2305.2002 |
0.407 |
|
| 2002 |
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, ... Mulligan M, et al. Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A Jaids Journal of Acquired Immune Deficiency Syndromes. 29: 254-261. DOI: 10.1097/00042560-200203010-00005 |
0.529 |
|
| 2001 |
Kaslow RA, Rivers C, Tang J, Bender TJ, Goepfert PA, El Habib R, Weinhold K, Mulligan MJ, Clements-Mann ML, Schwartz D, Belshe R, Gorse G, Frey S, Dolin R, Keefer M, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines Journal of Virology. 75: 8681-8689. PMID 11507213 DOI: 10.1128/Jvi.75.18.8681-8689.2001 |
0.545 |
|
| 2001 |
Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects Vaccine. 19: 3033-3042. PMID 11311997 DOI: 10.1016/S0264-410X(01)00051-2 |
0.477 |
|
| 2001 |
Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, ... ... Mulligan M, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. The Journal of Infectious Diseases. 183: 1343-52. PMID 11294665 DOI: 10.1086/319863 |
0.557 |
|
| 2001 |
Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 19: 2080-91. PMID 11228380 DOI: 10.1016/S0264-410X(00)00415-1 |
0.395 |
|
| 2000 |
Goepfert PA, Bansal A, Edwards BH, Ritter GD, Tellez I, McPherson SA, Sabbaj S, Mulligan MJ. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. Journal of Virology. 74: 10249-55. PMID 11024158 DOI: 10.1128/Jvi.74.21.10249-10255.2000 |
0.418 |
|
| 2000 |
Sabbaj S, Mulligan MJ, Hsieh RH, Belshe RB, McGhee JR. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group. Aids (London, England). 14: 1365-74. PMID 10930151 DOI: 10.1097/00002030-200007070-00009 |
0.538 |
|
| 2000 |
Bansal A, Shaw KL, Edwards BH, Goepfert PA, Mulligan MJ. Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env. Journal of Virology. 74: 2949-54. PMID 10684317 DOI: 10.1128/Jvi.74.6.2949-2954.2000 |
0.337 |
|
| 1999 |
Mulligan MJ, Weber J. Human trials of HIV-1 vaccines Aids. 13. PMID 10885769 |
0.426 |
|
| 1999 |
Goepfert PA, Shaw K, Wang G, Bansal A, Edwards BH, Mulligan MJ. An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes Journal of Virology. 73: 7210-7217. PMID 10438808 DOI: 10.1128/Jvi.73.9.7210-7217.1999 |
0.315 |
|
| 1999 |
Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. The Journal of Infectious Diseases. 180: 290-8. PMID 10395842 DOI: 10.1086/314895 |
0.479 |
|
| 1999 |
Tellez I, Sabbaj S, Peng X, Mulligan MJ. T cell and antibody responses in HIV-1 seronegative volunteers immunized with recombinant canarypox and gp120 prime-boost vaccines Journal of Investigative Medicine. 47. |
0.464 |
|
| 1998 |
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers Aids. 12: 2407-2415. PMID 9875578 DOI: 10.1097/00002030-199818000-00009 |
0.584 |
|
| 1998 |
Giddings AM, Ritter GD, Mulligan MJ. The matrix protein of HIV-1 is not sufficient for assembly and release of virus-like particles Virology. 248: 108-116. PMID 9705260 DOI: 10.1006/Viro.1998.9284 |
0.401 |
|
| 1998 |
Salzwedel K, West JT, Mulligan MJ, Hunter E. Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. Journal of Virology. 72: 7523-31. PMID 9696849 DOI: 10.1128/Jvi.72.9.7523-7531.1998 |
0.387 |
|
| 1998 |
Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. The Journal of Infectious Diseases. 177: 310-9. PMID 9466516 DOI: 10.1086/514209 |
0.554 |
|
| 1998 |
Tello J, Soong SJ, Hunter B, Meriwether R, Hook EW, Mulligan MJ. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. The American Journal of the Medical Sciences. 315: 11-6. PMID 9427569 DOI: 10.1016/S0002-9629(15)40265-4 |
0.463 |
|
| 1997 |
Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MJ, Desrosiers RC. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus Journal of Virology. 71: 7711-7718. PMID 9311855 DOI: 10.1128/Jvi.71.10.7711-7718.1997 |
0.362 |
|
| 1997 |
Ball JM, Mulligan MJ, Compans RW. Basolateral sorting of the HIV type 2 and SIV envelope glycoproteins in polarized epithelial cells: Role of the cytoplasmic domain Aids Research and Human Retroviruses. 13: 665-675. PMID 9168235 DOI: 10.1089/Aid.1997.13.665 |
0.394 |
|
| 1996 |
Goepfert PA, Ritter J, Peng X, Gbakima AA, Zhang Y, Mulligan MJ. Analysis of West African hunters for foamy virus infections Aids Research and Human Retroviruses. 12: 1725-1730. PMID 8959250 DOI: 10.1089/Aid.1996.12.1725 |
0.371 |
|
| 1996 |
Ritter GD, Yamshchikov G, Cohen SJ, Mulligan MJ. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. Journal of Virology. 70: 2669-73. PMID 8642705 DOI: 10.1128/Jvi.70.4.2669-2673.1996 |
0.417 |
|
| 1994 |
Belshe RB, Bolognesi DP, Clements ML, Corey L, Dolin R, Mestecky J, Mulligan M, Stablein D, Wright P. HIV infection in vaccinated volunteers. Jama. 272: 431. PMID 8040971 DOI: 10.1001/Jama.1994.03520060029015 |
0.553 |
|
| 1993 |
Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, Yamshchikov GV, Chen D, Eldridge JH. Protection against vaginal SIV transmission with microencapsulated vaccine Science. 260: 1323-1327. PMID 8493576 DOI: 10.1126/Science.8493576 |
0.501 |
|
| 1993 |
Ritter GD, Mulligan MJ, Lydy SL, Compans RW. Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain Virology. 197: 255-264. PMID 8212561 DOI: 10.1006/Viro.1993.1586 |
0.34 |
|
| 1992 |
Mulligan MJ, Ritter GD, Chaikinj MA, Yamshchikov GV, Kumar P, Hahn BH, Sweet RW, Compans RW. Human immunodeficiency virus type 2 envelope glycoprotein: Differential CD4 interactions of soluble gpl20 versus the assembled envelope complex Virology. 187: 233-241. PMID 1736526 DOI: 10.1016/0042-6822(92)90311-C |
0.412 |
|
| 1992 |
Mulligan MJ, Yamshchikov GV, Ritter GD, Gao F, Jin MJ, Nail CD, Spies CP, Hahn BH, Compans RW. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types Journal of Virology. 66: 3971-3975. PMID 1583738 DOI: 10.1128/Jvi.66.6.3971-3975.1992 |
0.41 |
|
| 1991 |
Wells DE, Chatterjee S, Mulligan MJ, Compans RW. Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons Journal of Virology. 65: 6325-6330. PMID 1920634 |
0.32 |
|
| 1990 |
Mulligan MJ, Kumar P, Hui H, Owens RJ, Ritter GD, Hahn BH, Compans RW. The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation Aids Research and Human Retroviruses. 6: 707-720. PMID 2364016 DOI: 10.1089/Aid.1990.6.707 |
0.42 |
|
| 1990 |
Owens RJ, Tanner CC, Mulligan MJ, Srinivas RV, Compans RW. Oligopeptide inhibitors of HIV-induced syncytium formation Aids Research and Human Retroviruses. 6: 1289-1296. PMID 2078410 DOI: 10.1089/Aid.1990.6.1289 |
0.419 |
|
| Show low-probability matches. |